Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results

G. Vendemiale, G. Palasciano, F. Cirelli, M. Altamura, A. De Vincentiis, E. Altomare

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Crystalline lactulose (Laevolac Cristalli®, CAS 4618-18-2), a pure form of the disaccharide widely employed in the therapy of complications of liver cirrhosis, was administered, after a pharmacological wash-out of 10 days and following a randomized design, to 10 cirrhotic patients for 30 days at the dosage of 60 g/d, while another 10 subjects with similar characteristics received no treatment. Besides the parameters usually monitored for the evaluation of liver function and state of hepatic encephalopathy, immunological patterns such as lymphocyte subpopulations CD 3, CD 4, CD 8, CD 16 (NK), CD 25 and antibacterial activity against Ty 2 strain of Salmonella typhi were evaluated. At the end of the study (day 30) a significant decrease of blood ammonia was observed, as expected, only in the group treated with lactulose with respect to the control group, as well as a significant increase of CD 16 and antibacterial activity (1/3); an enhanced level of CD 25, although not significant, was also noticed in the treated group with respect to the control group. These findings seem to show an effect of activation on cell-mediated immune system depressed during liver cirrhosis, produced by lactulose. Further studies are needed to confirm these data and to clarify the possible mechanisms involved.

Original languageEnglish
Pages (from-to)969-972
Number of pages4
JournalArzneimittel-Forschung/Drug Research
Volume42
Issue number7
Publication statusPublished - 1992

Fingerprint

Lactulose
Liver Cirrhosis
Liver
Crystalline materials
Salmonella
Lymphocytes
Disaccharides
Immune system
Ammonia
Salmonella typhi
Control Groups
Hepatic Encephalopathy
Lymphocyte Subsets
Blood
Therapeutics
Chemical activation
Immune System
Pharmacology

Keywords

  • CAS 4618-18-2
  • lactulose, clinical studies, crystalline
  • Laevolac Cristalli®
  • liver cirrhosis
  • liver therapeutics

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Vendemiale, G., Palasciano, G., Cirelli, F., Altamura, M., De Vincentiis, A., & Altomare, E. (1992). Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results. Arzneimittel-Forschung/Drug Research, 42(7), 969-972.

Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results. / Vendemiale, G.; Palasciano, G.; Cirelli, F.; Altamura, M.; De Vincentiis, A.; Altomare, E.

In: Arzneimittel-Forschung/Drug Research, Vol. 42, No. 7, 1992, p. 969-972.

Research output: Contribution to journalArticle

Vendemiale, G, Palasciano, G, Cirelli, F, Altamura, M, De Vincentiis, A & Altomare, E 1992, 'Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results', Arzneimittel-Forschung/Drug Research, vol. 42, no. 7, pp. 969-972.
Vendemiale, G. ; Palasciano, G. ; Cirelli, F. ; Altamura, M. ; De Vincentiis, A. ; Altomare, E. / Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results. In: Arzneimittel-Forschung/Drug Research. 1992 ; Vol. 42, No. 7. pp. 969-972.
@article{7fd6deb1315040f09156b1e20a2a62de,
title = "Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results",
abstract = "Crystalline lactulose (Laevolac Cristalli{\circledR}, CAS 4618-18-2), a pure form of the disaccharide widely employed in the therapy of complications of liver cirrhosis, was administered, after a pharmacological wash-out of 10 days and following a randomized design, to 10 cirrhotic patients for 30 days at the dosage of 60 g/d, while another 10 subjects with similar characteristics received no treatment. Besides the parameters usually monitored for the evaluation of liver function and state of hepatic encephalopathy, immunological patterns such as lymphocyte subpopulations CD 3, CD 4, CD 8, CD 16 (NK), CD 25 and antibacterial activity against Ty 2 strain of Salmonella typhi were evaluated. At the end of the study (day 30) a significant decrease of blood ammonia was observed, as expected, only in the group treated with lactulose with respect to the control group, as well as a significant increase of CD 16 and antibacterial activity (1/3); an enhanced level of CD 25, although not significant, was also noticed in the treated group with respect to the control group. These findings seem to show an effect of activation on cell-mediated immune system depressed during liver cirrhosis, produced by lactulose. Further studies are needed to confirm these data and to clarify the possible mechanisms involved.",
keywords = "CAS 4618-18-2, lactulose, clinical studies, crystalline, Laevolac Cristalli{\circledR}, liver cirrhosis, liver therapeutics",
author = "G. Vendemiale and G. Palasciano and F. Cirelli and M. Altamura and {De Vincentiis}, A. and E. Altomare",
year = "1992",
language = "English",
volume = "42",
pages = "969--972",
journal = "Arzneimittel-Forschung/Drug Research",
issn = "0004-4172",
publisher = "Editio Cantor Verlag GmbH",
number = "7",

}

TY - JOUR

T1 - Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results

AU - Vendemiale, G.

AU - Palasciano, G.

AU - Cirelli, F.

AU - Altamura, M.

AU - De Vincentiis, A.

AU - Altomare, E.

PY - 1992

Y1 - 1992

N2 - Crystalline lactulose (Laevolac Cristalli®, CAS 4618-18-2), a pure form of the disaccharide widely employed in the therapy of complications of liver cirrhosis, was administered, after a pharmacological wash-out of 10 days and following a randomized design, to 10 cirrhotic patients for 30 days at the dosage of 60 g/d, while another 10 subjects with similar characteristics received no treatment. Besides the parameters usually monitored for the evaluation of liver function and state of hepatic encephalopathy, immunological patterns such as lymphocyte subpopulations CD 3, CD 4, CD 8, CD 16 (NK), CD 25 and antibacterial activity against Ty 2 strain of Salmonella typhi were evaluated. At the end of the study (day 30) a significant decrease of blood ammonia was observed, as expected, only in the group treated with lactulose with respect to the control group, as well as a significant increase of CD 16 and antibacterial activity (1/3); an enhanced level of CD 25, although not significant, was also noticed in the treated group with respect to the control group. These findings seem to show an effect of activation on cell-mediated immune system depressed during liver cirrhosis, produced by lactulose. Further studies are needed to confirm these data and to clarify the possible mechanisms involved.

AB - Crystalline lactulose (Laevolac Cristalli®, CAS 4618-18-2), a pure form of the disaccharide widely employed in the therapy of complications of liver cirrhosis, was administered, after a pharmacological wash-out of 10 days and following a randomized design, to 10 cirrhotic patients for 30 days at the dosage of 60 g/d, while another 10 subjects with similar characteristics received no treatment. Besides the parameters usually monitored for the evaluation of liver function and state of hepatic encephalopathy, immunological patterns such as lymphocyte subpopulations CD 3, CD 4, CD 8, CD 16 (NK), CD 25 and antibacterial activity against Ty 2 strain of Salmonella typhi were evaluated. At the end of the study (day 30) a significant decrease of blood ammonia was observed, as expected, only in the group treated with lactulose with respect to the control group, as well as a significant increase of CD 16 and antibacterial activity (1/3); an enhanced level of CD 25, although not significant, was also noticed in the treated group with respect to the control group. These findings seem to show an effect of activation on cell-mediated immune system depressed during liver cirrhosis, produced by lactulose. Further studies are needed to confirm these data and to clarify the possible mechanisms involved.

KW - CAS 4618-18-2

KW - lactulose, clinical studies, crystalline

KW - Laevolac Cristalli®

KW - liver cirrhosis

KW - liver therapeutics

UR - http://www.scopus.com/inward/record.url?scp=0026639246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026639246&partnerID=8YFLogxK

M3 - Article

C2 - 1418064

AN - SCOPUS:0026639246

VL - 42

SP - 969

EP - 972

JO - Arzneimittel-Forschung/Drug Research

JF - Arzneimittel-Forschung/Drug Research

SN - 0004-4172

IS - 7

ER -